13 min listen
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
FromShort Wave
ratings:
Length:
14 minutes
Released:
Mar 13, 2023
Format:
Podcast episode
Description
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough to definitively say if the drug is effective for Black people. "[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," says Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School. On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.
Released:
Mar 13, 2023
Format:
Podcast episode
Titles in the series (100)
Exploring The Rainforest With 'TreeTop Barbie': Pioneering ecologist Nalini Nadkarni takes us up into the canopy — the area above the forest floor — where she helped research and document this unexplored ecosystem. by Short Wave